Geron Q2 2026: RYTELO Growth Support Guidance
Geron (GERN) reported Q2 2026 results, citing RYTELO (imetelstat) net product revenue of $57.5M, up 17% YoY. Net loss was $16.7M, slightly wider than $16.4M. Cash and marketable securities totaled $327M at June 30. For FY 2026, Geron guided RYTELO revenue of $220M to $240M and operating expenses of $230M to $240M. Wedbush reiterated an outperform rating and set a $6 price target.
How this was made
The 30-second read
Why it matters
Traders can update forward revenue expectations using the reiterated FY 2026 RYTELO net product revenue range and operating expense guidance, while monitoring whether ordering growth continues.
Market read
A biotech earnings-and-guidance update with explicit FY revenue and expense ranges, plus a stated cash runway, can drive model revisions and near-term positioning.
What to watch
The article does not quantify Phase 3 IMpactMF progress (enrollment, endpoints, timing), so trial-related risk remains a key swing factor beyond the revenue guidance.
Background
Geron’s RYTELO (imetelstat) is its commercial-stage product, with additional value tied to the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis.
Ticker impact
Geron reported Q2 2026 RYTELO net product revenue of $57.5M (+17% YoY) and reiterated FY guidance of $220M to $240M.
Likely supportive for near-term sentiment, with upside/downside tied to whether RYTELO ordering momentum sustains into the next quarters.
The article provides concrete quarterly revenue growth, cash position, and full-year revenue and operating expense guidance, which traders can use to update expectations and models.
Market effects
Adds incremental datapoints on commercial traction for an oncology specialty drug (imetelstat/RYTELO), relevant to small-cap biotech sentiment.
No specific regional market linkage beyond US small-cap biotech risk appetite.
International expansion language is present, but no country-specific regulatory or commercial milestones are disclosed.
Counterpoint
Despite revenue growth, the net loss widened slightly and inventory-related charges could signal cost or supply-chain pressure that may reappear.
Key entities
- companyGeron Corporation
Reported Q2 2026 results, reiterated FY 2026 RYTELO revenue guidance, and discussed Phase 3 IMpactMF progress.
- productRYTELO (imetelstat)
Commercial product whose net product revenue grew 17% YoY in Q2 and is guided to $220M to $240M for FY 2026.
- clinical_programIMpactMF Phase 3 trial
Ongoing Phase 3 program referenced as being advanced in relapsed/refractory myelofibrosis.
